Valsartan and Poor venous access - a phase IV clinical study of FDA data

Summary:

Poor venous access is reported as a side effect among people who take Valsartan (valsartan), especially for people who are female, 60+ old, also take Metformin, and have Crohn's disease.

The phase IV clinical study analyzes which people have Poor venous access when taking Valsartan. It is created by eHealthMe based on reports of 62,763 people who have side effects when taking Valsartan from the FDA, and is updated regularly.

What is Valsartan?

Valsartan has active ingredients of valsartan. It is often used in high blood pressure. eHealthMe is studying from 63,805 Valsartan users. Check the latest studies of Valsartan.

What is Poor venous access?

Poor venous access is found to be associated with 678 drugs and 481 conditions by eHealthMe. Check the latest studies of Poor venous access.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

62,763 people reported to have side effects when taking Valsartan.
Among them, 66 people (0.11%) have Poor venous access.

Could Valsartan cause Poor venous access?

Among these 66 people:

What is the gender of people who have Poor venous access when taking Valsartan? *

female: 72.5 %
male: 27.5 %

What is the age of people who have Poor venous access when taking Valsartan? *

What are other drugs people take besides Valsartan? *

What are other side effects people have besides Poor venous access? *

Hypotension (abnormally low blood pressure): 28 people, 42.42%
Nasopharyngitis (inflammation of the nasopharynx): 22 people, 33.33%
Stress And Anxiety: 22 people, 33.33%
Joint Pain: 19 people, 28.79%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 18 people, 27.27%
Weakness: 18 people, 27.27%
Dizziness: 18 people, 27.27%
Heart Rate Decreased: 18 people, 27.27%
Blood Pressure Systolic Increased: 17 people, 25.76%
Thrombosis (formation of a blood clot inside a blood vessel): 16 people, 24.24%

What are the existing conditions these people have? *

Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 18 people, 27.27%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 17 people, 25.76%
Fabry's Disease (build up of a particular type of fat, called globotriaosylceramide, in the body's cells): 14 people, 21.21%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 10 people, 15.15%
Back Pain: 7 people, 10.61%
Immunodeficiency Common Variable: 5 people, 7.58%
Pain: 4 people, 6.06%
High Blood Cholesterol: 3 people, 4.55%
Eye Disorder: 3 people, 4.55%
Diabetes: 2 people, 3.03%

* Approximation only. Some reports may have incomplete information.

Do you take Valsartan and have Poor venous access?

- Check whether Poor venous access is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Valsartan:

Valsartan (63,805 reports)

Browse all side effects of Valsartan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Poor venous access:

Poor venous access (678 drugs)

Browse all the conditions that are associated with Poor venous access:

Poor venous access (481 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on valsartan (the active ingredients of Valsartan) and Valsartan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.